Paragraph IV Patent Challenges: The Complete Strategic Playbook for Generic Entry, Brand Defense, and Settlement Arbitrage
The Drug Price Competition and Patent Term Restoration Act of 1984 — the Hatch-Waxman Act — is the single piece […]
Pharmaceutical Reverse Engineering IP: The Complete Analyst’s Playbook for Deformulation, Patent Thickets, and Global Safe Harbor Strategy
Generic and biosimilar drugs saved the U.S. healthcare system $445 billion in 2023 alone, accumulating to over $2.9 trillion across
505(b)(2) Pricing & Market Access: The Complete Commercial Playbook
Section 1: The 505(b)(2) Value Proposition — Pricing Incremental Innovation 1.1 Why the Pathway Exists and What It Actually Does
505(b)(2) Pricing & Market Access: The Complete Commercial Playbook Read Post »
Drug Patent Citation Network Analysis: The Definitive Guide to Predicting Pharma’s Next Moves
Why Standard Patent Intelligence Is Failing You The patent cliff is no longer the right mental model. For two decades,
Drug Patent Data for University Tech Transfer: The Complete Strategic Playbook
University Technology Transfer Offices (TTOs) sit at one of the most commercially consequential intersections in American innovation: the point where
Drug Patent Data for University Tech Transfer: The Complete Strategic Playbook Read Post »
Excipient Exclusion Filters: The Formulator’s Playbook for De-Risking Drug Development and Building Durable IP
1. Why ‘Inactive’ Is a Dangerous Word: The Strategic Case for Excipient Scrutiny The Myth That Costs Billions The word
Drug Patent Expiry Decoded: The Payer’s Complete Guide to Patent Cliffs, Biosimilar Entry, and Formulary Budget Control
Section 1: The Strategic Landscape: Why Patent Intelligence Has Become a Core Payer Competency The Formulary Has Become a Battlefield
Paragraph IV Certifications: The Complete IP Strategy Guide for Generic Drug Market Dominance
1. What Paragraph IV Actually Is — and Why It Matters A Paragraph IV certification is a formal legal assertion
Clinical Trial Velocity: The Approval Signal Pharma Investors Are Missing
I. Executive Summary Clinical trial velocity is not a measure of how fast a sponsor pushes a molecule through regulatory
Clinical Trial Velocity: The Approval Signal Pharma Investors Are Missing Read Post »
